Vistagen Therapeutics (VTGN) FCF Margin (2011 - 2026)

Vistagen Therapeutics has disclosed FCF Margin across 10 years of filings, most recently posting 996.41% for Q2 2026.

• In Q2 2026, FCF Margin rose 675400.0% year-over-year to 996.41%; the TTM figure through Jun 2026 stood at 2493.33% (up 525652.0% YoY), while the FY2026 annual figure was 5235.3%, up 342663.0% from the prior year.
• FCF Margin came in at 996.41% for Q2 2026 at Vistagen Therapeutics, up from 3483.87% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 66393.33% in Q1 2025 to a low of 39456.92% in Q1 2022.
• Average FCF Margin over 5 years is 2682.5%, with a median of 4469.76% recorded in 2023.
• Year-over-year, FCF Margin surged 7065065 bps in 2025 and sank 6987720 bps in 2026.
• Over 5 years, FCF Margin stood at 5407.67% in 2022, then jumped by 78 bps to 1162.77% in 2023, then sank by 278 bps to 4393.16% in 2024, then plunged by 33 bps to 5827.39% in 2025, then surged by 83 bps to 996.41% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 996.41% in Q2 2026, 3483.87% in Q1 2026, and 5827.39% in Q4 2025.